Lung Cancer Case Studies
Non-Small Cell Lung Cancer (NSCLC) strikes approximately 1 million people worldwide per year, with approximately 172,470 new cases occurring in the United States annually.
Targeted therapeutics are providing a promising view of the future in terms of first and second line treatment for NSCLC and other solid tumors. However, it has been a challenge to identify molecular, histopathological, and clinical phenotypes which can help to better randomize clinical trials, and to identify responders to these promising therapeutics.